PRF Technologies Ltd

Research PRF Technologies Ltd (PRFX) on Bullrun: market cap USD 779.18K. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 779.18K.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 17.00K-USD 5.02M-USD 3.96M-311.8%-7.47USD 3.13MUSD 21.00KUSD 8.54M
FY2024USD 0-USD 14.59M-USD 12.63Mn/a-105.52USD 4.26MUSD 59.00KUSD 1.82M
FY2023USD 0-USD 9.34M-USD 6.69Mn/a-122.94USD 8.03MUSD 86.00KUSD 7.24M
FY2022n/a-USD 8.79M-USD 6.47Mn/a-63.46USD 4.10Mn/aUSD 11.02M
FY2021n/a-USD 7.25M-USD 6.60Mn/a-7.25USD 16.54Mn/aUSD 18.08M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 779.18Kn/an/an/a
20252025-12-31USD 2.51Mn/an/an/a
20242024-12-31USD 4.94Mn/an/an/a
20232023-12-29USD 1.07Mn/an/an/a
20222022-12-30USD 1.10Mn/an/an/a
20212021-12-31USD 3.47Mn/an/an/a

About PRF Technologies Ltd

PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company was formerly known as PainReform Ltd. and changed its name to PRF Technologies Ltd.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is PRF Technologies Ltd's market cap?

PRF Technologies Ltd's market capitalization is USD 779.18K.

What does PRF Technologies Ltd do?

PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company was formerly known as PainReform Ltd. and changed its name to PRF Technologies Ltd. in January 2026. PRF Technologies Ltd.